Craft

Grindeks

Revenue

€141.4 M

FY, 2019

Grindeks Summary

Company Summary

Overview
Grindeks, a pharmaceutical company, engages in the research, development, manufacture and sale of generics and active pharmaceutical ingredients. It offers heart and cardiovascular drugs, CNS drugs, and anti-cancer medication therapeutic groups under the Mildronate and Ftorafur brands; and Oxytocin, a hormone that is used as a medication to facilitate childbirth. 
Type
Private
Status
Active
Founded
1991
HQ
Rīga, LV | view all locations
Website
https://grindeks.com/
Cybersecurity rating
Sectors

Key People

  • Juris Bundulis

    Juris Bundulis, Chairman of the Board

    • Evija Krinkele

      Evija Krinkele, Head of Registration Dossier Development Group

      • Juris Hmelnickis

        Juris Hmelnickis, Chairman of the Board

        • Kirovs Lipmans, Chairman of the Council

          LocationsView all

          11 locations detected

          • Rīga HQ

            Latvia

            53 Krustpils iela

          • Yerevan, Yerevan

            Armenia

            2/5 Armenak Armenakyan St

          • Bakı

            Azerbaijan

            64 Əhməd Cəmil Küçəsi

          • Minsk

            Belarus

            728 34 vulica Enhieĺsa

          • Tallinn, Harju maakond

            Estonia

            33 Tondi

          • Tbilisi, Tbilisi

            Georgia

            4 Besiki St

          and 5 others

          Grindeks Financials

          Summary Financials

          Revenue (Q3, 2020)
          €42.6M
          Gross profit (Q3, 2020)
          €24.8M
          Net income (Q3, 2020)
          (€691.0K)
          Cash (Q3, 2020)
          €2.5M
          EBIT (Q3, 2020)
          €4.5M

          Footer menu